Hanmi Pharmaceutical Co., Ltd.
http://www.hanmipharm.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Hanmi Pharmaceutical Co., Ltd.
How Korea Can Avoid Pitfalls Of Over-Reliance On Out-Licensing
An over-reliance on out-licensing as a business model may restrict the healthy growth of South Korean biopharma firms over the longer term, a Citeline executive told a recent symposium in Seoul.
Korea Q3 Roundup: Mixed Results Amid Focus On Obesity, New Drugs
As Korean firms report quarterly earnings, Hanmi is stepping up the development of obesity drugs, Daewoong unveils plans to boost sales of in-house new drugs, GC Biopharma’s immunoglobulin undergoes the US approval process and Ildong has set up a new R&D-focused subsidiary.
How Korea Can Avoid Pitfalls Of Over-Reliance On Out-Licensing
An over-reliance on out-licensing as a business model may restrict the healthy growth of South Korean biopharma firms over the longer term, a Citeline executive told a recent symposium in Seoul.
Hanmi’s GLP-1 Obesity Contender Gets Phase III Nod In Korea
Hanmi aims to commercialize its GLP-1 obesity treatment, the first one from its ambitious HOP project, within three years as it moves to Phase III in Korea.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Beijing Hanmi Pharmaceutical Co., Ltd.
- Hanmi Holdings Co., Ltd
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice